Lil­ly ex­ec says de­vel­op­ing new ther­a­pies for lu­pus is 'in scope'

Last year
R&D
Pharma

Amarin names new CEO as Patrick Holt de­parts

Last year
People

Sen­ate Fi­nance Chair press­es HHS to crack down on cy­ber­se­cu­ri­ty in wake of Unit­ed­Health at­tack

Last year
Pharma
FDA+

Am­gen's Up­liz­na suc­ceeds in Phase 3 tri­al for rare au­toim­mune dis­ease

Last year
R&D

Ore­gon ju­ry says J&J owes talc claimant $260M

Last year
Pharma
Law

FDA hands Chi­nese drug man­u­fac­tur­er a Form 483 not­ing em­ploy­ees de­stroyed doc­u­ments 

Last year
China
FDA+

AI is un­like­ly to take off among CD­MOs at the same scale as bio­phar­ma com­pa­nies, in­sid­ers say

Last year
AI
Manufacturing

Ar­riVent inks ADC deal with Al­pham­ab; An­nex­on's $125M of­fer­ing

Last year
News Briefing

Rayze­Bio warned of po­ten­tial iso­tope sup­ply is­sues be­fore BMS deal

Last year
R&D
Manufacturing

Cy­to­ki­net­ics CEO ad­dress­es ac­qui­si­tion ru­mors, says buy­er walked away, SEC fil­ing shows

Last year
Deals

Ra­dio­phar­ma­ceu­ti­cal com­pa­ny Telix aims for $202M IPO

Last year
Financing
R&D

BioN­Tech co-founder Özlem Türe­ci on ‘hip’ AD­Cs and the pow­er of com­bo ther­a­pies

Last year
People
R&D

Up­dat­ed: Lil­ly de­tails mid-stage win for tirzepatide in MASH with fi­bro­sis da­ta

Last year
R&D

Vir's ear­ly Phase 2 he­pati­tis D da­ta show re­duc­tion, re­moval of virus with com­bo and monother­a­py

Last year
R&D

Lykos’ MD­MA-as­sist­ed ther­a­py stum­bles at ad­comm amid ques­tions about study, safe­ty and abuse

Last year
Pharma
FDA+

House law­mak­ers float trans­paren­cy re­forms for 340B pro­gram at hear­ing

Last year
Pharma
FDA+

UK's NICE rec­om­mends Lil­ly's Zep­bound for weight loss

Last year
Pharma

Viking ex­pands on Phase 2b da­ta for NASH drug, tout­ing his­to­log­i­cal end­points

Last year
R&D

Cor­rect­ed: Vilya rais­es $21M in Se­ries A ex­ten­sion; Sh­iono­gi to open re­search cen­ter in San Diego

Last year
News Briefing

Up­dat­ed: What the first five par­tic­i­pants for FDA's Op­er­a­tion Warp Speed for rare dis­eases are tack­ling

Last year
Cell/Gene Tx
FDA+

No­vo Hold­ings’ head of Asia on in­vest­ing in ‘Chi­na for Chi­na,’ and stay­ing out of biotech (for now)

Last year
Financing
China

Bris­tol My­er­s' Op­di­vo-Yer­voy beats Lenvi­ma and Nex­avar in Phase 3 ear­ly liv­er can­cer tri­al

Last year
R&D

Bridge­Bio spot­lights 12 and 18-month da­ta for po­ten­tial achon­dropla­sia drug in chil­dren

Last year
R&D

An­nex­on pro­claims Phase 3 win for com­ple­ment in­hibitor in Guil­lain-Bar­ré syn­drome

Last year
R&D
First page Previous page 147148149150151152153 Next page Last page
A service from the Financial Times